Search by keywords: Connect with us Stay Informed. Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters. Newsletter Sign Up 1842 News Items found Sunrise Day Camp: Where Kids with Cancer — and Their Siblings — Can Be Kids for the Summer Tuesday, July 24, 2018 Discover how Sunrise Association Day Camps are transforming summer for children affected by cancer. Finding Research Advances the Genetic Understanding of Pineoblastoma, a Rare Brain Cancer Friday, July 20, 2018 The findings will lead to more accurate diagnoses and, potentially, to better treatments. In the Clinic A Family Discovers an Unexpected Cancer Risk in Their Genes Thursday, July 19, 2018 Two brothers discuss their surprise at being diagnosed with Lynch syndrome. Finding Double Jeopardy: Gene-Sequencing Test Uncovers New Clues about a Defect Seen in Many Tumors Wednesday, July 18, 2018 MSK researchers have found that a genetic state in tumors called whole-genome doubling is connected with worse outcomes for people with cancer. In the Lab Splicing May Be an Effective Target in the Fight against Cancer Wednesday, July 18, 2018 New drugs are being developed that target part of the process to make proteins. In the Clinic Six Things to Know about Soft Tissue Sarcoma Recurrence Tuesday, July 17, 2018 If you've been treated for soft tissue sarcoma, a recurrence may be a big concern for you. Here's what MSK's sarcoma experts think you should know about the disease coming back. MSK Researchers Have Identified a Doubling Chromosome That Can Help Predict Outcomes in People with Cancer Monday, July 16, 2018 Experts at Memorial Sloan Kettering Cancer Center (MSK) have identified genome doubling in cancer and have correlated it to a worse prognosis across cancer types. Using MSK-IMPACT™ to analyze matched tumor and normal DNA, MSK researchers were able to identify an abnormality in tumors known as genome doubling. This doubling occurs in 28 percent of all cancers and could have significant implications for treatment options in the future. Feature New Imaging Technique Provides Snapshot of Brain Tumor Activity Friday, July 13, 2018 A new imaging approach could shorten the time needed to determine whether a brain tumor treatment is working. Feature Meet the Unsung Immune Cell that Could Change Immunotherapy Thursday, July 12, 2018 A lesser-known immune cell is suddenly getting more attention in the field of cancer immunology. Findings from People with Acute Myeloid Leukemia Point to a New Understanding of Drug Resistance Thursday, July 5, 2018 Drug resistance is a formidable challenge in cancer treatment. A drug called enasidenib (Idhifa®) was approved by the US Food and Drug Administration last year for the treatment of people with a form of acute myeloid leukemia (AML) that’s driven by a mutation in the gene IDH2. About 15 percent of people with AML have this mutation. Research led by Memorial Sloan Kettering Cancer Center (MSK) reports that people who take enasidenib can develop resistance to it — in a way never seen before. Enasidenib works differently than most cancer drugs. Rather than killing leukemia cells, it turns them into normal blood cells. The discovery of this unique resistence may lead to more-precise treatments for people with AML in the future. Pagination Load More Book traversal links for Newsroom Previous Newsroom Next Cancer Vaccine Could Prevent Neuroblastoma From Returning After Antibody Treatment